Combining immune checkpoint inhibition plus tyrosine kinase inhibition as first and subsequent treatments for metastatic renal cell carcinoma.

Yuanquan YangSarah P PsutkaAnish B ParikhMingjia LiKatharine CollierAbdul MiahSherry V MoriMegan HinkleyScott S TykodiEvan HallJohn A ThompsonMing Yin

Published in: Cancer medicine (2022)

ICI/TKI combination therapy is feasible and safe beyond the first-line setting. Prior treatment history appears to impact efficacy but has a lesser effect on safety/tolerability.

Keyphrases

tyrosine kinase
combination therapy
metastatic renal cell carcinoma
epidermal growth factor receptor
open label
clinical trial
randomized controlled trial
double blind
study protocol